Taken together, our findings support the hypothesis that the NLRP3 inflammasome is a potential therapeutic target for AD and suggest GNVs as an effective treatment to prevent cytotoxicity and disease-related oxidative stress. This evidence concerns the gene NLRP3 and Alzheimer disease.